Edition:
United States

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

2.09USD
25 Sep 2017
Change (% chg)

$-0.03 (-1.42%)
Prev Close
$2.12
Open
$2.10
Day's High
$2.16
Day's Low
$2.09
Volume
20,365
Avg. Vol
15,281
52-wk High
$5.69
52-wk Low
$1.66

Chart for

About

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management... (more)

Overall

Beta: 2.38
Market Cap(Mil.): $32.71
Shares Outstanding(Mil.): 15.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Orexigen Therapeutics Q2 loss per share $2.00

* Orexigen Therapeutics announces second quarter 2017 financial results

Aug 08 2017

BRIEF-Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

* Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

Aug 07 2017

BRIEF-Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave to Egypt

* Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave® (naltrexone hcl / bupropion hcl extended release) to Egypt

Jul 26 2017

BRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67

* Orexigen Therapeutics reports financial results for the first quarter ended March 31, 2017

May 09 2017

BRIEF-Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba

* NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®

May 02 2017

BRIEF-Orexigen Therapeutics announces new drug submission for Contrave in Canada

* Orexigen Therapeutics Inc announces new drug submission for Contrave© in canada

Apr 25 2017

BRIEF-Orexigen Therapeutics on March 28, 2017, entered into controlled equity offering sales agreement

* Orexigen Therapeutics Inc- on March 28, 2017, entered into a controlled equity offering sales agreement - sec filing

Mar 30 2017

BRIEF-Orexigen Therapeutics reports Q4 loss per share $1.69

* Orexigen Therapeutics reports financial results for the fourth quarter and year ended December 31, 2016

Mar 28 2017

Earnings vs. Estimates